A novel, broad-spectrum antimicrobial combination for the treatment of Pseudomonas aeruginosa corneal infections.
A novel, broad-spectrum antimicrobial combination for the treatment of Pseudomonas aeruginosa corneal infections.
Antimicrob Agents Chemother. 2019 Jul 22;:
Authors: Chojnacki M, Philbrick A, Scherzi T, Pecora N, Dunman PM, Wozniak RAF
Abstract
Bacterial keratitis causes significant blindness, yet antimicrobial resistance has rendered current treatments ineffective. Polymyxin B/trimethoprim (PT) and rifampicin has potent in vitro activity against Staphylococcus aureus and Pseudomonas aeruginosa, two important causes of keratitis. Here we further characterize this combination against P. aeruginosa in a murine keratitis model. PT + rifampicin performed comparably or better than moxifloxacin, the gold standard, suggesting the combination may be a promising therapy for bacterial keratitis.
PMID: 31332071 [PubMed - as supplied by publisher]
Source: Antimicrobial Agents and Chemotherapy - Category: Microbiology Authors: Chojnacki M, Philbrick A, Scherzi T, Pecora N, Dunman PM, Wozniak RAF Tags: Antimicrob Agents Chemother Source Type: research
More News: Antimicrobial Resistance | Avelox | Blindness | Chemotherapy | Microbiology | Moxifloxacin | Opthalmology | Polymyxin B | Staphylococcus Aureus | Trimethoprim